Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 102Neoplasm Metastasis 26Neoplasms 15Brain Neoplasms 13Prostatic Neoplasms 10Endometrial Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 7Glioblastoma 7Glioma 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Breast Diseases 5Sarcoma 4Recurrence 4Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Sarcoma, Ewing 3Osteosarcoma 3Neoplasms by Site 3Multiple Myeloma 3Meningioma 3Melanoma 3Carcinoma, Renal Cell 3Unilateral Breast Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Oligodendroglioma 2

Interventions

Cisplatin 180Radiotherapy 81Paclitaxel 80Brachytherapy 74Carboplatin 72pembrolizumab 63Bevacizumab 40Surveys and Questionnaires 29Colposcopy 29Radiation 28Gemcitabine 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 27Topotecan 26Magnetic Resonance Spectroscopy 24Blood Specimen Collection 23human papillomavirus vaccine, L1 type 16, 18 22Nivolumab 22Drug Therapy 21Papillomavirus Vaccines 20atezolizumab 19Platinum 19Radiotherapy, Intensity-Modulated 18Biopsy 18Docetaxel 17Taxes 16Cyclophosphamide 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14fludarabine 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × abemaciclib × Clear all
NCT05768139 2026-05-22

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡